Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
825 3 |
Ultima descărcare din IBN: 2023-11-08 20:43 |
SM ISO690:2012 MUSTEAŢĂ, Vasile. Actualităţi în managementul leucemiei mieloide cronice: experienţa IMSP institutul oncologic şi reviewul literaturii
. In: Analele Ştiinţifice ale USMF „N. Testemiţanu”, 2010, nr. 3(11), pp. 343-351. ISSN 1857-1719. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Analele Ştiinţifice ale USMF „N. Testemiţanu” | ||||||
Numărul 3(11) / 2010 / ISSN 1857-1719 | ||||||
|
||||||
Pag. 343-351 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Updates in the management of chronic myeloid leukemia: experience of the institute of oncology and review of literature
The contemporary management of chronic myeloid leukemia diversifies the diagnostic
and curative options with respect to the level of medical assistance. The treatment of chronic myeloid leukemia in the chronic phase and accelerated phase without complications may be realized in the outpatient department or in daily stationary. The treatment of chronic myeloid leukemia in the accelerated phase with complications (bleeding, thrombotic, infectious) and in the acute phase should be realized in the specialized departments of hematology. The drug Imatinib Mesylate constitutes the first-line therapeutic option in the chronic phase and in the accelerated phase, being superior to the conventional chemotherapy and α-Interferon due to the possibility of achievement of a fast complete clinico-hematologic response, complete cytogenetic response and due to the considerable increase of a life quality and longevity of patients. |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-3118</cfResPublId> <cfResPublDate>2010-10-01</cfResPublDate> <cfVol>11</cfVol> <cfIssue>3</cfIssue> <cfStartPage>343</cfStartPage> <cfISSN>1857-1719</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/3118</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Actualităţi în managementul leucemiei mieloide cronice: experienţa IMSP institutul oncologic şi reviewul literaturii </cfTitle> <cfAbstr cfLangCode='EN' cfTrans='o'>Updates in the management of chronic myeloid leukemia: experience of the institute of oncology and review of literature The contemporary management of chronic myeloid leukemia diversifies the diagnostic and curative options with respect to the level of medical assistance. The treatment of chronic myeloid leukemia in the chronic phase and accelerated phase without complications may be realized in the outpatient department or in daily stationary. The treatment of chronic myeloid leukemia in the accelerated phase with complications (bleeding, thrombotic, infectious) and in the acute phase should be realized in the specialized departments of hematology. The drug Imatinib Mesylate constitutes the first-line therapeutic option in the chronic phase and in the accelerated phase, being superior to the conventional chemotherapy and α-Interferon due to the possibility of achievement of a fast complete clinico-hematologic response, complete cytogenetic response and due to the considerable increase of a life quality and longevity of patients.</cfAbstr> <cfAbstr cfLangCode='RO' cfTrans='o'>Managementul contemporan al leucemiei mieloide cronice diversifică opţiunile diagnostice şi curative în funcţie de nivelul asistenţei medicale. Tratamentul leucemiei mieloide cronice în faza cronică şi de accelerare fără complicaţii poate fi efectuat în condiţii de ambulator sau a staţionarului de zi. Tratamentul leucemiei mieloide cronice în faza de accelerare cu complicaţii (hemoragice, trombotice, infecţioase) şi acută se efectuează în secţiile specializate de hematologie. Medicamentul Imatinib Mesilat constituie opţiune terapeutică de prima linie în faza cronică şi de accelerare a leucemiei mieloide cronice, fiind net superioară în raport cu chimioterapie convenţională şi α-IFN prin posibilitatea atingerii răspunsului clinico-hematologic complet rapid, răspunsului citogenetic complet şi creşterea semnificativă a calităţii vieţii şi longevităţii pacienţilor.</cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-10-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2010-10-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11430</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2010-10-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11430</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11430-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2010-10-01T24:00:00</cfStartDate> <cfFamilyNames>Musteaţă</cfFamilyNames> <cfFirstNames>Vasile</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>